

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and a Waiver under 21 U.S.C. §355 (n)(4)

Maha Hussain, M.D.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: July 24, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to New Drug Application (NDA) 022-042, Evista (raloxifene hydrochloride) Tablets, Eli Lilly and Company, proposed indications for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis, and for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of breast cancer, I am eligible to receive a waiver under 21 U.S.C. §355(n) (4).

| Type of Interest | Nature | Magnitude |
|-------------------------|-------------------|--|
| Stock | Sponsor | Valued at less than \$5,001 |
| Stock | 2 Competing Firms | Valued between \$5,001 and \$25,000 per firm |

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

/S/
Signature of SGE

June 8, 2007
Date